A detailed history of Acuta Capital Partners, LLC transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Acuta Capital Partners, LLC holds 21,000 shares of ASND stock, worth $2.8 Million. This represents 3.18% of its overall portfolio holdings.

Number of Shares
21,000
Holding current value
$2.8 Million
% of portfolio
3.18%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$113.0 - $153.43 $2.37 Million - $3.22 Million
21,000 New
21,000 $3.14 Million
Q3 2020

Nov 16, 2020

SELL
$134.29 - $154.32 $7.45 Million - $8.56 Million
-55,500 Closed
0 $0
Q2 2020

Aug 14, 2020

SELL
$110.87 - $156.01 $853,699 - $1.2 Million
-7,700 Reduced 12.18%
55,500 $8.21 Million
Q1 2020

May 15, 2020

BUY
$97.01 - $145.11 $3.95 Million - $5.91 Million
40,700 Added 180.89%
63,200 $7.12 Million
Q4 2019

Feb 14, 2020

BUY
$91.45 - $139.12 $2.06 Million - $3.13 Million
22,500 New
22,500 $3.13 Million
Q4 2018

Feb 14, 2019

SELL
$55.16 - $69.67 $3.94 Million - $4.98 Million
-71,500 Closed
0 $0
Q3 2018

Nov 07, 2018

SELL
$63.77 - $76.28 $15.3 Million - $18.3 Million
-239,611 Reduced 77.02%
71,500 $5.07 Million
Q2 2018

Aug 15, 2018

SELL
$58.55 - $73.92 $13.6 Million - $17.2 Million
-232,889 Reduced 42.81%
311,111 $20.7 Million
Q1 2018

May 15, 2018

BUY
$38.98 - $68.04 $506,739 - $884,520
13,000 Added 2.45%
544,000 $35.6 Million
Q4 2017

Feb 14, 2018

BUY
$31.98 - $40.38 $991,380 - $1.25 Million
31,000 Added 6.2%
531,000 $21.3 Million
Q3 2017

Nov 14, 2017

BUY
$26.89 - $37.1 $13.4 Million - $18.6 Million
500,000
500,000 $18.1 Million

Others Institutions Holding ASND

About Ascendis Pharma A/S


  • Ticker ASND
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,810,200
  • Market Cap $7.45B
  • Description
  • Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...
More about ASND
Track This Portfolio

Track Acuta Capital Partners, LLC Portfolio

Follow Acuta Capital Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Acuta Capital Partners, LLC with notifications on news.